SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?
Sodium glucose co-transporter type 2 inhibitors (SGLT-2 inhibitors) are a class of antidiabetics, recently approved for the treatment of patients with T2DM. They feature cardioprotective and renoprotective action, while they exert beneficial effects on metabolic parameters. Non-alcoholic fatty liver...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karolinum Press
2018-04-01
|
| Series: | Acta Medica |
| Subjects: | |
| Online Access: | https://actamedica.lfhk.cuni.cz/60/4/0167/ |